Curis (CRIS) Competitors $1.62 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.93%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRIS vs. SABS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, and INCYShould you be buying Curis stock or one of its competitors? The main competitors of Curis include SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry. Curis vs. Its Competitors SAB Biotherapeutics Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Curis (NASDAQ:CRIS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Do institutionals & insiders believe in CRIS or SABS? 30.0% of Curis shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 5.7% of Curis shares are held by company insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CRIS or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Curis-341.24% N/A -102.22% SAB Biotherapeutics N/A -153.92%-89.16% Which has stronger valuation & earnings, CRIS or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Curis. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.91M1.86-$43.39M-$4.88-0.33SAB Biotherapeutics$1.32M18.45-$34.10M-$4.00-0.59 Which has more risk and volatility, CRIS or SABS? Curis has a beta of 3.86, indicating that its share price is 286% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Does the media prefer CRIS or SABS? In the previous week, Curis had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Curis and 0 mentions for SAB Biotherapeutics. Curis' average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score. Company Overall Sentiment Curis Neutral SAB Biotherapeutics Neutral Do analysts recommend CRIS or SABS? Curis currently has a consensus price target of $17.00, indicating a potential upside of 949.38%. SAB Biotherapeutics has a consensus price target of $9.75, indicating a potential upside of 316.67%. Given Curis' higher possible upside, equities research analysts plainly believe Curis is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00SAB Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummarySAB Biotherapeutics beats Curis on 9 of the 16 factors compared between the two stocks. Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.25M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-0.3321.8485.6327.59Price / Sales1.86477.40622.26138.47Price / CashN/A47.6737.7861.77Price / Book-2.2810.1513.136.76Net Income-$43.39M-$52.31M$3.30B$275.88M7 Day Performance-2.99%6.72%5.27%3.71%1 Month Performance-5.26%15.01%9.92%10.21%1 Year Performance-67.66%29.35%87.69%35.86% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris1.7849 of 5 stars$1.62flat$17.00+949.4%-67.7%$20.25M$10.91M-0.3360Positive NewsAnalyst ForecastSABSSAB Biotherapeutics3.6754 of 5 stars$1.95-3.0%$9.75+400.0%-14.6%$20.93MN/A-0.49140BOLTBolt Biotherapeutics2.5111 of 5 stars$5.26-3.0%$47.50+803.0%-53.7%$10.40M$7.69M-0.2090Positive NewsAnalyst ForecastHigh Trading VolumeAMGNAmgen4.5623 of 5 stars$273.97+0.4%$309.70+13.0%-6.9%$146.96B$33.42B22.4028,000Positive NewsAnalyst UpgradeGILDGilead Sciences4.8857 of 5 stars$112.62+0.5%$117.17+4.0%+38.3%$139.09B$28.75B22.4317,600Positive NewsAnalyst ForecastVRTXVertex Pharmaceuticals4.8015 of 5 stars$395.31+2.5%$493.81+24.9%-8.5%$98.90B$11.02B28.266,100Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.7524 of 5 stars$560.75-0.6%$817.67+45.8%-41.4%$59.77B$14.21B14.1315,106Positive NewsAnalyst ForecastALNYAlnylam Pharmaceuticals4.0627 of 5 stars$447.49+0.2%$439.58-1.8%+72.3%$58.51B$2.25B-181.172,230Analyst ForecastBIIBBiogen4.5908 of 5 stars$138.52+0.8%$182.04+31.4%-17.0%$20.14B$9.68B13.247,605Analyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3366 of 5 stars$424.31-1.9%$449.57+6.0%+30.6%$19.52B$2.88B16.561,305Analyst ForecastInsider TradeINCYIncyte4.5046 of 5 stars$83.89+1.4%$83.67-0.3%+32.6%$16.15B$4.24B19.072,617Analyst Forecast Related Companies and Tools Related Companies SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Amgen Competitors Gilead Sciences Competitors Vertex Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRIS) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
